Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets

General Physiology and Biophysics

Volumn 24, Issue 1, 2005, Pages 113-128

  Fišar, Zdeněk ^a   Anders, M ^a   Kalisova L ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Antidepressant; Platelets; Serotonin uptake

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; LITHIUM CARBONATE; MAPROTILINE; MOCLOBEMIDE; SEROTONIN;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DATA ANALYSIS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG SELECTIVITY; EX VIVO STUDY; IC 50; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MEMBRANE PERMEABILITY; MICHAELIS CONSTANT; NONHUMAN; RAT; REVIEW; SEROTONIN BLOOD LEVEL; SEROTONIN UPTAKE; THROMBOCYTE; THROMBOCYTE KINETICS; THROMBOCYTE RICH PLASMA;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANTIDEPRESSIVE AGENTS; BLOOD PLATELETS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; KINETICS; MEN; METABOLIC CLEARANCE RATE; RATS; RATS, WISTAR; SEROTONIN;

ANIMALIA; RATTUS NORVEGICUS;

EID: 19144370346     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Alvarez J. C., Gluck N., Fallet A., Gregoire A., Chevalier J. F., Advenier C., Spreux-Varoquaux O. (1999a): Plasma serotonin level after 1 day of fluoxetine treatment: a biological predictor for antidepressant response? Psychopharmacology (Berl.) 143, 97-101
2. Alvarez J. C., Sanceaume M., Advenier C., Spreux-Varoquaux O. (1999b): Differential changes in brain and platelet 5-HT concentrations after steady-state achievement and repeated administration of antidepressant drugs in mice. Eur. Neuropsychopharmacol. 10, 31-36
3. Artigas F., Sarrias M. J., Martinez E., Gelpi E., Alvarez E., Udina. C. (1989): Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium. Psychopharmacology (Berl.) 99, 328-332
4. Ashina, S., Bendtsen L., Jensen R. (2004): Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition. Pain 108, 108-114
5. Bakish D., Cavazzoni P., Chudzik J., Ravindran A., Hrdina P. D. (1997): Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biol. Psychiatry 41, 184-190
6. Baumann P. (1992): Clinical pharmacokinetics of citalopram and other selective serotonergic reuptake inhibitors (SSRI). Int. Clin. Psychopharmacol. 6 (Suppl. 5), 13-20
7. Bel N., Artigas F. (1999): Modulation of the extracellular 5-hydroxytryptamine brain concentrations by the serotonin and noradrenaline reuptake inhibitor, milnacipran. Neuropsychopharmacology 21, 745-754
8. Bennett J. P. Jr., Yamamura H. I. (1985): Neurotransmitter, hormone, or drug receptor binding methods. In: Neurotransmitter Receptor Binding (Eds. H. I. Yamamura, S. J. Enna and M. J. Kuhar), pp. 61-89 (2nd ed.), Raven Press, New York
9. Bevan J. A., Bevan R. D., Shreeve S. M. (1989): Variable receptor affinity hypothesis. FASEB J. 3, 1696-1704
10. Bianchi M., Moser C., Lazzarini C., Vecchiato E., Crespi F. (2002): Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes. Exp. Brain Res. 143, 191-197
11. Blakely R. D., Ramamoorthy S., Schroeter S., Qian Y., Apparsundaram S., Galli A., DeFelice L. J. (1998): Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol. Psychiatry 44, 169-178
12. Erba A., Castrogiovanni P. (2002): Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. J. Clin. Psychopharmacol. 22, 131-136
13. Blier P., de Montigny C. (1994): Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15, 220-226
14. Block E. R., Edwards D. (1987): Effect of plasma membrane fluidity on serotonin transport by endothelial cells. Am. J. Physiol. 253, C672-678
15. Bonhomme N., Esposito E. (1998): Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: a review. J. Clin. Psychopharmacol. 18, 447-454
16. Bourdeaux R., Desor D., Lehr P. R., Younos C., Capolaghi B. (1998): Effects of fluoxetine and norfluoxetine on 5-hydroxytryptamine metabolism in blood platelets and brain after administration to rats. J. Pharm. Pharmacol. 50, 1387-1392
17. Caldecott-Hazard S., Morgan D. G., DeLeon-Jones F., Overstreet D. H., Janowsky D. (1991): Clinical and biochemical aspects of depressive disorders: II. transmitter/receptor theories. Synapse 9, 251-301
18. Castrogiovanni P., Blardi P., De Lalla A., Dell'Erba A., Auteri A. (2003): Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression? Psychopharmacol. Bull. 37, 102-108
19. Charney D. S., Delgado P. L. (1992): Current concepts of the role of serotonin function in depression and anxiety. In: Serotonin Receptor Subtypes: Pharmacological Significance and Clinical Implications (Eds. S. Z. Langer, N. Brunello, G. Racagni and J. Mendlewicz), Vol. 1., pp. 89-104, Int. Acad. Biomed. Drug Res., Karger, Basel
20. Costa J. L., Silber S. A., Murphy D. L. (1977): Effects of reserpine and imipramine on vesicular serotonin uptake and storage in intact human platelets. Life Sci. 21, 181-188
21. 1B receptor antagonist critically depends on the dose of citalopram. Eur. J. Pharmacol. 397, 63-74
22. Cremers T. I. F., Spoelstra E. N., de Boer P., Bosker F. J., Mørk A., den Boer J. A., Westerink B. H., Wikström H. V. (2000b): Desensitisation of 5-HT autoreceptors upon pharmacokinetically monitored chronic treatment with citalopram. Eur. J. Pharmacol. 397, 351-357
23. Dordoni P. L., Frassanito L., Bruno M. F., Proietti R., de Cristofaro R., Ciabattoni G., Ardito G., Crocchiolo R., Landolfi R., Rocca B. (2004): In vivo and in vitro effects of different anaesthetics on platelet function. Br. J. Haematol. 125, 79-82
24. Duman R. S. (2002): Synaptic plasticity and mood disorders. Mol. Psychiatry 7 (Suppl. 1), S29-34
25. Duman R. S., Heninger G. R., Nestler E. J. (1997): A molecular and cellular theory of depression. Arch. Gen. Psychiatry 54, 597-606
26. Eriksson E., Engberg G., Bing O., Nissbrandt H. (1999): Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology 20, 287-296
27. Fleckenstein A. E., Haughey H. M., Metzger R. R., Kokoshka J. M., Riddle E. L., Hanson J. E., Gibb J. W., Hanson G. R. (1999): Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur. J. Pharmacol. 382, 45-49
28. Franke L., Schewe H.-J., Müller B., Campman V., Kitzrow W., Uebelhack R., Berghöfer A., Müller-Oerlinghausen B. (2000): Serotonergic platelet variables in unmedicated patients suffering from major depression and healthy subjects. Relationship between 5HT content and 5HT uptake. Life Sci. 67, 301-315
29. Fuller R. W. (1994): Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci. 55, 163-167
30. Glue P. W., Cowen P. J., Nutt D. J., Kolakowska T., Grahame-Smith D. G. (1986): The effect of lithium on 5-HT-mediated neuroendocrine responses and platelet 5-HT receptors. Psychopharmacology (Berl.) 90, 398-402
31. Haase J., Killian A.-M., Magnani F., Williams C. (2001): Regulation of the serotonin transporter by interacting proteins. Biochem. Soc. Trans. 29, 722-728
32. Harwood A. J., Agam G. (2003): Search for a common mechanism of mood stabilizers. Biochem. Pharmacol. 66, 179-189
33. Hjorth S., Auerbach S. B. (1999): Autoreceptors remain functional after prolonged treatment with a serotonin reuptake inhibitor. Brain Res. 835, 224-228
34. Jančinová V., Májeková M., Nosál' R., Petríková M. (1996): Inhibition of blood platelet functions by cationic amphiphilic drugs in relation to their physico-chemical properties. Blood Coagul. Fibrinolysis 7, 191-193
35. Javors M. A., Houston J. P., Tekell J. L., Brannan S. K., Frazer A. (2000): Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. Int. J. Neuropsychopharmacol. 3, 229-235
36. Kitamura R., Hirakata H., Okuda H., Sato M., Toda H., Nakamura K., Hatano Y., Urabe N., Fukuda K. (2001): Thiopental enhances human platelet aggregation by increasing arachidonic acid release. Can. J. Physiol. Pharmacol. 79, 854-860
37. Lachman H. M., Papolos D. F. (1995): A molecular model for bipolar affective disorder. Med. Hypotheses 45, 255-264
38. Langer S. Z., Schoemaker H. (1988): Effects of antidepressants on monoamine transporters. Prog. Neuropsychopharmacol. Biol. Psychiatry 12, 193-216
39. Lesch K.-P., Wolozin B. L., Murphy D. L., Riederer P. J. (1993): Primary structure of the human platelet serotonin uptake site - identity with the brain-serotonin transporter. J. Neurochem. 60, 2319-2322
40. Lestra C., d'Amato T., Ghaemmaghami C., Perret-Liaudet A., Broyer M., Renaud B., Dalery J., Chamba G. (1998): Biological parameters in major depression: effects of paroxetine, viloxazine, moclobemide, and electroconvulsive therapy. Relation to early clinical outcome. Biol. Psychiatry 44, 274-280
41. Lucki I., O'Leary O. F. (2004): Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. J. Clin. Psychiatry 65 (Suppl. 4), 11-24
42. Maes M., Meltzer H. Y. (1995): The serotonin hypothesis of major depression. In: Psychopharmacology: The Fourth Generation of Progress (Eds. F. E. Bloom and D. J. Kupfer), pp. 933-944, Raven Press, New York
43. 3H-paroxetine binding to platelets from healthy volunteers. Biol. Psychiatry 34, 356-360
44. Manji H. K. (1992): G proteins: implications for psychiatry. Am. J. Psychiatry 149, 746-760
45. Maurer-Spurej E., Pittendreigh C., Solomons K. (2004): The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb. Haemost. 91, 119-128
46. Mellerup E., Langer S. Z. (1990): Validity of imipramine platelet binding-sites as a biological marker of endogenous-depression - A World Health-Organization-Collaborative Study. Pharmacopsychiatry 23, 113-117
47. Meltzer H. Y., Lowy M. T. (1987): The serotonin hypothesis of depression. In: Psychopharmacology: The Third Generation of Progress. pp. 513-526, Raven Press, New York
48. Meltzer H. Y., Arora R. C., Baber R., Tricou B. J. (1981): Serotonin uptake in blood platelets of psychiatric patients. Arch. Gen. Psychiatry 38, 1322-1326
49. Moret C., Briley M. (1996): Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain. Eur. J. Pharmacol. 295, 189-197
50. Murphy D. L. (1990): Peripheral indices of central serotonin function in humans. Ann. N. Y. Acad. Sci. 600, 282-295
51. 2). Thromb. Res. 105, 339-345
52. Ortiz J., Artigas F., Gelpi E. (1988): Serotonergic status in human blood. Life Sci. 43, 983-990
53. Owens M. J. (2004): Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J. Clin. Psychiatry 65 (Suppl. 4), 5-10
54. Pandey G. N., Pandey S. C., Dwivedi Y., Sharma R. P., Janicak P. G., Davis J. M. (1995): Platelet serotonin-2A receptors: a potential biological marker for suicidal behavior. Am. J. Psychiatry 152, 850-855
55. Pandey G. N., Pandey S. C., Ren X., Dwivedi Y., Janicak P. G. (2003): Serotonin receptors in platelets of bipolar and schizoaffective patients: effect of lithium treatment. Psychopharmacology (Berl.) 170, 115-123
56. Poirier M. F., Galzin A. M., Pimoule C., Schoemaker H., Le Quan Bui K. H., Meyer P., Gay C., Loo H., Langer S. Z. (1988): Short-term lithium administration to healthy volunteers produces long-lasting pronounced changes in platelet serotonin uptake but not imipramine binding. Psychopharmacology (Berl.) 94, 521-526
57. Ramamoorthy S., Blakely R. D. (1999): Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 285, 763-766
58. Rodbard D., Lenox R. H., Wray H. L., Ramseth D. (1976): Statistical characterization of the random errors in the radioimmunoassay dose-response variable. Clin. Chem. 22, 350-358
59. Sakai N., Kodama N., Ohmori S., Sasaki K., Saito N. (2000): Involvement of the actin cytoskeleton in the regulation of serotonin transporter (SET) activity: possible mechanism underlying SET regulation by protein kinase C. Neurochem. Int. 36, 567-579
60. Scanlon S. M., Williams D. C., Schloss P. (2001): Membrane cholesterol modulates serotonin transporter activity. Biochemistry 40, 10507-10513
61. Seydel J. K., Velasco M. A., Coats E. A., Cordes H. P., Kunz B., Wiese M. (1992): The importance of drug-membrane interaction in drug research and development. Quant. Struct.-Act. Relat. 11, 205-210
62. Sheridan N. P., Block E. R. (1988): Serotonin transport and fluidity in plasma membrane vesicles: effect of hyperoxia. Am. J. Physiol. 254, C781-787
63. Shiah I.-S., Yatham L. N. (2000): Serotonin in mania and in the mechanism of action of mood stabilizers: a review of clinical studies. Bipolar Disord. 2, 77-92
64. Shinitzky M. (1984): Membrane fluidity and receptor function. In: Membrane Fluidity (Eds. M. Kates and L. A. Manson), pp. 585-601, Plenum Publ. Corp., New York
65. Siever L. J., Kahn R. S., Lawlor B. A., Trestman R. L., Lawrence T. L., Coccaro E. F. (1991): II. Critical issues in defining the role of serotonin in psychiatric disorders. Pharmacol. Rev. 43, 509-525
66. Slotkin T. A., Whitmore W. L., Dew K. L., Kilts C. D. (1986): Uptake of serotonin into rat platelets and synaptosomes: comparative structure-activity relationships, energetics and evaluation of the effects of acute and chronic nortriptyline administration. Brain Res. Bull. 17, 67-73
67. Stahl S. M. (1985): Peripheral models for the study of neurotransmitter receptors in man. Psychopharmacol. Bull. 21, 663-671
68. Stahl S. M. (1992): Serotonin receptors and the mechanism of action of antidepressant drugs: postmortem, platelet, and neuroendocrine studies in depressed patients. In: Serotonin IA Receptors in Depression and Anxiety (Eds. S. M. Stahl, M. Gastpar, J. M. Keppel Hesselink and J. Traber), pp. 119-134, Raven Press, New York
69. 1A receptors and pharmacotherapy. Is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol. Bull. 30, 39-43
70. Stahl S. M. (2000): Essential Psychopharmacology. Neuroscientific Basis and Practical Applications. (2nd ed.), Cambridge University Press, Cambridge
71. Stahl S. M., Meltzer H. Y. (1978): A kinetic and pharmacologic analysis of 5-hydroxytryptamine transport by human platelets and platelet storage granules: comparison with central serotonergic neurons. J. Pharmacol. Exp. Ther. 205, 118-132
72. Tuomisto J., Tukiaien E., Ahlfors U. G. (1979): Decreased uptake of 5-hydroxytryptamine in blood platelets from patients with endogenous depression. Psychopharmacology 65, 141-147
73. Turčáni P., Nosál' R., Turi-Nagy L. (1982): On the serotonin liberation from rat platelets due to betaadrenoceptor blocking drugs. Thromb. Res. 28, 213-221
74. Van Den Berg E. K. Jr., Schmitz J., M., Benedict C. R., Prewitt J. B., Malloy C. R., Willerson J. T., Dehmer G. J. (1987): Plasma serotonin concentrations: validation of a sampling technique using long catheters. Am. J. Med. Sci. 294, 324-327
75. Zhou F. C., Tao-Cheng J. H., Segu. L., Patel T., Wang Y. (1998): Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res. 805, 241-254